Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Breast Cancer

Breast Cancer

105 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Breast Cancer

1185 trials tracked for Breast Cancer: 221 in phase 3 or 4 and 97 with published results. The most-cited published study has 2627 citations.

1,185Trials tracked
221Phase 3 & 4
0Recruiting
97With published results
Phase distribution
Phase 4 32 Phase 3 189 Phase 2 548 Phase 1 87 Other / NA 329
  1. Phase 3 A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE) Completed · 2,627 cited
  2. Phase 3 A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE) Completed · 2,157 cited
  3. Phase 3 Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases Completed · 1,665 cited
  4. Phase 3 Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer Completed · 1,513 cited
  5. Phase 3 Surgery to Remove Sentinel Lymph Nodes With or Without Removing Lymph Nodes in the Armpit in Treating Women With Breast Cancer Completed · 1,080 cited
  6. Phase 3 Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid Completed · 1,022 cited
Show 44 more trials
  1. Phase 3 Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer Completed · 748 cited
  2. Phase 3 Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer Completed · 727 cited
  3. Phase 3 Study of Faslodex +/- Concomitant Arimidex v Exemestane Following Progression on Non-steroidal Aromatase Inhibitors Completed · 723 cited
  4. Phase 3 Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer Completed · 702 cited
  5. Phase 3 Maintenance Treatment With Capecitabine Versus Observation in Breast Cancer Patients Completed · 699 cited
  6. Phase 3 S0500 Treatment Decision Making Based on Blood Levels of Tumor Cells for Metastatic Breast Cancer Treated With Chemo Completed · 650 cited
  7. Phase 3 Letrozole in Breast Cancer Who Have Received 5 Years of Aromatase Inhibitor Therapy Completed · 650 cited
  8. Phase 3 Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment. Completed · 604 cited
  9. Phase 3 Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer Completed · 562 cited
  10. Phase 3 S0230 Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer Completed · 543 cited
  11. Phase 3 Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor Completed · 541 cited
  12. Phase 3 Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer Completed · 492 cited
  13. Phase 3 Accelerated Partial Breast Irradiation Using Intensity Modulated Radiotherapy Versus Whole Breast Irradiation Completed · 465 cited
  14. Phase 3 Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer Completed · 434 cited
  15. Phase 3 Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Completed · 421 cited
  16. Phase 3 Clodronate With or Without Chemotherapy and/or Hormonal Therapy in Treating Women With Stage I or Stage II Breast Cancer Completed · 378 cited
  17. Phase 3 S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer Completed · 374 cited
  18. Phase 3 DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02] Completed · 352 cited
  19. Phase 3 A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer Completed · 347 cited
  20. Phase 3 A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment Completed · 345 cited
  21. Phase 3 A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery Completed · 324 cited
  22. Phase 3 A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer Completed · 322 cited
  23. Phase 3 Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer Completed · 307 cited
  24. Phase 3 A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer Completed · 229 cited
  25. Phase 3 S0715: Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, II, or IIIA Breast Cancer Undergoing Chemo Completed · 213 cited
  26. Phase 3 Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer Completed · 205 cited
  27. Phase 3 Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy Completed · 197 cited
  28. Phase 3 Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel Completed · 193 cited
  29. Phase 3 A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer Completed · 167 cited
  30. Phase 3 A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer Completed · 166 cited
  31. Phase 3 Secondary Adjuvant Long Term Study With Arimidex Completed · 161 cited
  32. Phase 3 Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC) Completed · 153 cited
  33. Phase 3 Study of Efficacy and Safety of Myl1401O + Taxane vs Herceptin©+ Taxane for 1st Line, Met. Br. Ca. Completed · 145 cited
  34. Phase 3 Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast Cancer Completed · 144 cited
  35. Phase 3 Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line in Postmenopausal Women Completed · 133 cited
  36. Phase 3 Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase Inhibitors Completed · 133 cited
  37. Phase 3 Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer Completed · 129 cited
  38. Phase 3 Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast Cancer Completed · 122 cited
  39. Phase 4 Study Of MK-0752 In Combination With Tamoxifen Or Letrozole to Treat Early Stage Breast Cancer Completed · 118 cited
  40. Phase 3 S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone Therapy Completed · 118 cited
  41. Phase 3 A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer Completed · 114 cited
  42. Phase 3 S0927:Omega3-Fatty Acid Supp in Treating Muscle&Bone Pain&Stiffness in Pts W/Stg I,II,III Brst Canc Rec'v Hormone Thpy Completed · 101 cited
  43. Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer Completed · 100 cited
  44. Phase 3 Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Women With HER2-positive Early Breast Cancer Completed · 98 cited

Showing the 50 most-cited and recently-updated of 1,185 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Breast Cancer: what the trials found

Evidence regarding the management of breast cancer includes findings on endocrine therapy and subcutaneous administration methods. Morning administration of endocrine therapy was associated with a decrease in endocrine toxicity and tolerability at 12 weeks (-2.2; -5.0) and varied impacts on health-related quality of life scores 2.

The use of a fixed dose combination of Pertuzumab and Trastuzumab for subcutaneous use (PH FDC SC) showed significant patient preference for home administration over hospital settings in various cohorts, with percentages ranging from 1.2% to 69.0% 3. Additionally, healthcare provider responses regarding drug preparation areas during the neoadjuvant phase varied significantly across different groups 3.

Recent results — preliminary, needs further review

  • Giredestrant was associated with a significant reduction in the proliferative index (Ki67 expression) of -14.5 and -10.0 (p=0.002) 8.
  • Alpelisib showed a decrease in Ki67 percentage across multiple groups (-0.46 to -0.68) 10.
  • Omega-3 fatty acid supplementation resulted in measurable changes in the percentage of total fatty acids for various polyunsaturated fatty acid (PUFA) groups compared to baseline or aromatase inhibitor therapy alone 6.
  • Restriction Spectrum Imaging (RSI) demonstrated a statistically significant difference in diagnostic accuracy compared to conventional breast MRI in screening populations (p=<0.05) 19.
  • Invasive interstitial fluid pressure (IFP) showed a statistically significant difference based on malignancy status (20.9 vs 9.9, p=0.008) 13.

For the clinician treating this condition

  • Morning administration of endocrine therapy is associated with improved tolerability and reduced toxicity at the 12-week mark.
  • Subcutaneous delivery of Pertuzumab and Trastuzumab (PH FDC SC) shows high potential for patient preference in home settings compared to hospital-based administration.
  • Giredestrant and Alpelisib are associated with reductions in Ki67 expression, a key marker of cellular proliferation.

AI synthesis of 7 cited trials, updated Jun 20, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
26 Gy in 5 fractions non-inferior to 40 Gy in 15 fractions for breast cancer recurrence at 10 years
Oncology RCT
26 Gy in 5 fractions non-inferior to 40 Gy in 15 fractions for breast cancer recurrence at 10 years Shorter radiation treatment works just as well for breast cancer patients after surgery
This phase 3 randomised trial compared two hypofractionated radiotherapy schedules (26 Gy and 27 Gy in 5 fractions) with standard 40 Gy in 1…
Doctors found that giving five days of lower-dose radiation is safe and effective. This option helps patients recover faster without increas…
Jun 6, 2026
Datopotamab deruxtecan showed no overall survival benefit versus investigator's choice chemotherapy in metastatic HR-positive breast cancer.
OB/GYN & Women's Health RCT
Datopotamab deruxtecan showed no overall survival benefit versus investigator's choice chemotherapy in metastatic HR-positive breast cancer. Datopotamab deruxtecan extends life for advanced breast cancer patients
This Phase III randomized controlled trial evaluated datopotamab deruxtecan versus investigator's choice chemotherapy in patients with inope…
New drug datopotamab deruxtecan helps advanced breast cancer patients live longer and stay disease-free
Jun 4, 2026
Immunotherapy improves complete response but lacks overall response benefit in HR+ breast cancer
Oncology Meta-analysis
Immunotherapy improves complete response but lacks overall response benefit in HR+ breast cancer Immunotherapy shows mixed results for hormone-positive breast cancer patients
This systematic review and meta-analysis evaluated immunotherapy in patients with hormone receptor-positive and human epidermal growth facto…
A large analysis found immunotherapy did not improve overall survival but did increase side effects for hormone-positive breast cancer patie…
Jun 1, 2026
Meta-analysis finds higher complication rates with immediate versus delayed breast reconstruction
OB/GYN & Women's Health Meta-analysis
Meta-analysis finds higher complication rates with immediate versus delayed breast reconstruction Meta-analysis shows immediate breast reconstruction linked to higher implant complications
A large meta-analysis shows immediate breast reconstruction carries higher complication rates than delayed procedures, especially with impla…
A large analysis of over 73,000 patients found immediate breast reconstruction had higher complication rates than delayed surgery for implan…
Jun 1, 2026
Trastuzumab deruxtecan improves PFS vs chemotherapy in HR-positive, HER2-low breast cancer
OB/GYN & Women's Health RCT
Trastuzumab deruxtecan improves PFS vs chemotherapy in HR-positive, HER2-low breast cancer Trial shows T-DXd beats chemo for breast cancer
In a phase 3 RCT of 866 patients with HR-positive, HER2-low/-ultralow metastatic breast cancer after endocrine therapy, trastuzumab deruxtec…
A new drug, T-DXd, helps people with a common type of advanced breast cancer live longer without their disease getting worse.
Jun 1, 2026
TAC chemotherapy improves relapse-free survival in certain early breast cancer subtypes
OB/GYN & Women's Health RCT
TAC chemotherapy improves relapse-free survival in certain early breast cancer subtypes Doctors found that certain tumor markers might help choose the best cancer treatment plan for some patients
A randomized trial compared TAC to ddAC in early breast cancer. The authors observed improved relapse-free survival in specific tumor subtyp…
This study looked at how two different drug schedules worked for people with early breast cancer. Results suggest that specific tumor featur…
Jun 1, 2026
CE-MRI rules out malignancy in 13.1% pretest probability for high-risk breast lesions with 91.3% sensitivity
OB/GYN & Women's Health Meta-analysis
CE-MRI rules out malignancy in 13.1% pretest probability for high-risk breast lesions with 91.3% sensitivity Contrast MRI helps rule out cancer in high-risk breast lesions for many patients
This systematic review and meta-analysis evaluates contrast-enhanced breast MRI (CE-MRI) for ruling out malignancy in patients with high-ris…
A new analysis of 479 patients found that contrast-enhanced MRI could safely rule out cancer in many high-risk breast lesions, potentially a…
Jun 1, 2026
Meta-analysis of CDK4/6 inhibitor rechallenge shows improved progression-free survival in advanced breast cancer
Oncology Meta-analysis
Meta-analysis of CDK4/6 inhibitor rechallenge shows improved progression-free survival in advanced breast cancer Switching drugs offers hope for advanced breast cancer patients facing treatment failure
This meta-analysis synthesizes data from phase II and III clinical trials involving 1396 patients with hormone receptor-positive, HER2-negat…
A large review found that restarting a specific cancer drug after stopping it can delay disease growth by nearly two months compared to stan…
May 28, 2026
Narrative review examines microorganisms in breast cancer with limited evidence from cross-sectional studies and models
Infectious Disease Sys. Review
Narrative review examines microorganisms in breast cancer with limited evidence from cross-sectional studies and models Review of microorganisms and breast cancer evidence remains uncertain
This narrative review addresses the role of microorganisms in breast cancer. The authors note that the majority of evidence originates from …
A review of microorganisms and breast cancer shows evidence is weak because most data comes from cross-sectional studies and lab models.
Frontiers May 28, 2026
Review explores host-microbiome interactions in breast cancer
Oncology Sys. Review
Review explores host-microbiome interactions in breast cancer Scientists explore how gut bacteria might help fight breast cancer in the body
This narrative review examines the role of host-microbiome interactions in breast cancer. The authors synthesize evidence on how microbial c…
A recent review looks at how the microbes living in our gut could interact with treatments for breast cancer. While more research is needed,…
Frontiers May 25, 2026
Fulvestrant maintenance improves PFS versus capecitabine in HR+ HER2- metastatic breast cancer
Oncology RCT
Fulvestrant maintenance improves PFS versus capecitabine in HR+ HER2- metastatic breast cancer Fulvestrant maintenance therapy significantly improves progression free survival compared to capecitabine in hormone receptor positive metastatic breast cancer patients
This randomized phase 3 trial in 210 patients with HR+ HER2- metastatic breast cancer compared fulvestrant to capecitabine after first-line …
In a study of 210 patients in China, fulvestrant helped keep cancer from growing longer than capecitabine. Fewer serious side effects occurr…
May 22, 2026
Systematic review and network meta-analysis on exercise dose for cancer-related fatigue in breast cancer survivors
Primary Care & Family Medicine Meta-analysis
Systematic review and network meta-analysis on exercise dose for cancer-related fatigue in breast cancer survivors Breast Cancer Fatigue Lifts at This Exact Exercise Sweet Spot
This meta-analysis of 2,067 breast cancer survivors examined exercise for cancer-related fatigue. It found an inverted U-shaped dose-respons…
• Exercise only helps fatigue within specific weekly dose ranges • Breast cancer survivors struggling with constant tiredness • Evidence is …
Frontiers May 15, 2026

Questions about Breast Cancer

Is there any research on using AI for Breast Cancer pathology?

Yes, AI is being researched for breast cancer pathology, including digital pathology, deep learning for imaging, and machine learning for biomarker detection.

Full answer →
Can a plasma lipid panel help detect early stage Breast Cancer?

Yes, early research shows plasma lipid panels can help detect early-stage breast cancer, with machine learning models achieving high accuracy, but they are not yet standard clinical tests.

Full answer →
What are the new treatments for triple-negative and HER2-positive Breast Cancer?

New treatments for triple-negative breast cancer include chemo-immunotherapy (pembrolizumab plus platinum-based chemo) and potential NY-ESO-1 targeted therapies; for HER2-positive breast cancer, neoadjuvant targeted combinations and post-neoadjuvant trastuzumab emtansine are key

Full answer →
Does the PECS II block reduce morphine use after Breast Cancer surgery?

Yes, the PECS II block significantly reduces morphine use after breast cancer surgery, based on multiple randomized trials and a meta-analysis.

Full answer →
Can deep learning help doctors find Breast Cancer on tomosynthesis scans?

Yes, deep learning can help doctors find breast cancer on tomosynthesis scans, matching or improving radiologist accuracy in some cases.

Full answer →
See all 5 questions about Breast Cancer →